NEW YORK--(BUSINESS WIRE)--Jun 11, 2026--
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc (“Erasca” or the “Company”) (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611577362/en/
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ERAS-0015's preclinical data was based on improper comparisons to Revolution Medicines, Inc. ("RevMed") and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.
On April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca's ERAS-0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation, and that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures."
On this news, Erasca's stock price fell $2.34, or approximately 10.9%, from a closing price of $21.49 on April 24, 2026 to close at $19.15 per share on April 27, 2026.
On April 27, 2026, at approximately 4:17 p.m. EDT, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015, classified as a "Grade 3 TRAE of pneumonitis" that "progressed to Grade 5 after withdrawal of supportive care per patient decision," and further stating that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were "not based on any head-to-head clinical trials" and are "inherently limited and such data may not be directly comparable."
On this news, Erasca's stock price fell $9.25, or more than 45%, from a closing price of $19.15 per share on April 27, 2026 to close at $9.90 per share on April 28, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Erasca’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Erasca, Inc. class action, go to www.faruqilaw.com/ERAS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Erasca Securities Class Action Lawsuit:
What is the Erasca securities fraud lawsuit about?
The lawsuit alleges that Erasca and certain executives made false or misleading statements regarding ERAS-0015, a cancer drug candidate. Specifically, plaintiffs claim the company failed to disclose that ERAS-0015's preclinical data relied on improper comparisons to Revolution Medicines and exposed Erasca to potential patent and trade secret risks.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Erasca securities during the applicable Class Period and suffered financial losses may be eligible to participate in the lawsuit. Eligibility will depend on the specific allegations in the complaint and the timing of an investor's transactions.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed investor who helps represent the interests of all class members and works with counsel in directing the litigation. Investors who wish to serve as lead plaintiff in the Erasca action must file the appropriate motion with the court by the August 10, 2026 deadline.
What should investors do if they purchased Erasca stock during the Class Period?
Investors who purchased Erasca stock and incurred losses should review the allegations in the lawsuit, gather relevant trading records, and evaluate their legal options. Investors may contact counsel to learn more about the case, discuss potential claims, and determine whether to seek lead plaintiff status.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Erasca securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
ERAS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Erasca (ERA) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
